Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients

•In COVID-19 ill patients, VEGF involves in inflammatory responses along with the cytokine storm.•VEGF plays a key role in COVID-19 pathogenesis.•Medications which target the VEGF inhibition could be considered as a therapeutic potential. Recently, the medications used for the severe form of the cor...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2021-12, Vol.101 (Pt B), p.108257-108257, Article 108257
Main Authors: Sahebnasagh, Adeleh, Nabavi, Seyed Mohammad, Kashani, Hamid Reza Khayat, Abdollahian, Safieh, Habtemariam, Solomon, Rezabakhsh, Aysa
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Anti-VEGF therapy
Coronaviruses
COVID-19
COVID-19 - immunology
COVID-19 Drug Treatment
Critical Illness
Critically Ill Patients
Cytokine storm
Cytokines
Enzyme inhibitors
Health services
Humans
Inflammation
Kinases
Monoclonal antibodies
Pathogenesis
Patients
Protein-tyrosine kinase
Receptors, Vascular Endothelial Growth Factor - immunology
Respiratory distress syndrome
SARS-CoV-2
Therapeutic Target
Tyrosine
Vascular endothelial growth factor
Vascular Endothelial Growth Factors - antagonists & inhibitors
Vascular Endothelial Growth Factors - immunology
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•In COVID-19 ill patients, VEGF involves in inflammatory responses along with the cytokine storm.•VEGF plays a key role in COVID-19 pathogenesis.•Medications which target the VEGF inhibition could be considered as a therapeutic potential. Recently, the medications used for the severe form of the coronavirus disease-19 (COVID-19) therapy are of particular interest. In this sense, it has been supposed that anti-VEGF compounds would be good candidates in the face of “cytokine storm” and intussuscepted angiogenesis due to having an appreciable anti-inflammatory effect. Therefore, they can be subjected to therapeutic protocols to manage acute respiratory distress syndrome (ARDS). Since the compelling evidence emphasized that VEGFs contribute to the inflammatory process and play a mainstay role in disease pathogenesis, in this review, we aimed to highlight the VEGF's plausible participation in the cytokine storm exacerbation in COVID-19. Next, the recent clinical advances regarding the anti-VEGF medications, including humanized monoclonal antibody, immunosuppressant, a tyrosine kinase inhibitor, and a cytokine inhibitor, have been addressed in the setting of COVID-19 treatment in critically ill patients. Together, retrieving the increased level of VEGF subsets, as well as antagonizing VEGF related receptors, could be helpful for the treatment of COVID-19, especially in those suffering from ARDS.
ISSN:1567-5769
1878-1705
1878-1705
DOI:10.1016/j.intimp.2021.108257